As an exploration geologist, the Hamersley iron story has always fascinated me. For decades, we’ve treated the timeline of iron ore formation in the Pilbara’s Hamersley Province as almost gospel. We referenced phosphate dating and clast-bearing conglomerates as reliable benchmarks. But what happens when new geochronological tools rip apart that foundation?

If you're an investor in the Australian Stock Market, you may be curious about technology's growing impact on traditional industries. Artificial intelligence (AI) is revolutionizing how businesses operate and how investors assess potential returns. My learning curve in the space of AI is now my favourite topic of conversation. In the space of a month, my curiosity about this business has evolved from a casual conversation to one that is generating a passion for the business.

Investing in mineral exploration stocks on the ASX can offer exciting opportunities, but it also carries unique challenges. With over 30 years of experience as a geologist in the industry, I have witnessed both the highs and lows of the mineral resource market. I have seen proejcts go from a Urnaium project to being a Phosphate project in 6 months and Nickel to Gold or vice versa, in a simialr time frame. Knowing the complexities in this sector is vital for making informed i

In the crowded corridors of medtech innovation, it's easy to get swept up in buzzwords—AI-powered, minimally invasive, precision diagnostics. But every now and then, a company emerges with more than just jargon—it comes armed with transformative tech, a clear path to market, and the traction to back it up.

When it comes to spotting undervalued potential in biotech, I often look for companies that are not only developing novel technologies but also demonstrating clear paths to commercialisation. This month, three small-cap names on the ASX have really caught my attention: Memphasys Limited (ASX: MEM), Control Bionics (ASX: CBL), and dorsaVi Ltd (ASX: DVL). Each is on a very different mission, but all three are making measurable progress—and investors are starting to notice.

nvesting in small-cap stories on the ASX (Australian Stock Exchagne) in 2025 can seem overwhelming, especially for beginners. With the abundance of information available, it is crucial to know how to sift through it effectively to make informed decisions. As I have been in this industry for over 30 years and as an investor prior to the 1987 stockmarket crash, this blog will just outline some of my own experience and insights as to what has wroked for me over those years.

The narrative around critical minerals is no longer just a story of energy transition. It has become a complex intersection of economics, security, diplomacy, and market psychology. At first, it was about rare earths and lithium. Now the ripples have spread across copper, gold, iron ore, antimony, and more.

Something is refreshing about watching a discovery story unfold the right way. Not rushed. Not sensationalised. Just a methodical march of results — each one more confident than the last. That’s what we’re seeing with White Cliff Minerals (ASX: WCN) and their Rae Copper Project in Nunavut, Canada.

In my opinion, Tungsten should be one of the most critical metals on any investor's watchlist. The scarcity of the metal as an economical deposit, in my opinion, makes this metal high on the list. There are a few market factors that make Tungsten a very volatile commodity, and the China influence makes this metal difficult to predict in terms of its market value.

A discovery of a copper deposit usually comes with great excitement and is followed by narratives of great wealth generation. Over the recent decades, these type of discoveries are few and the reality for investors is fueled with disappointments and rhetoric of false narratives from the explorers.